Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
60,727,357
-
Shares change
-
-5,060,569
-
Total reported value, excl. options
-
$19,486,077
-
Value change
-
-$2,603,944
-
Number of buys
-
19
-
Number of sells
-
-31
-
Price
-
$0.3209
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2022
70 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q4 2022.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60,727,357 shares
.
Largest 10 shareholders include BROADWOOD CAPITAL INC (23,353,697 shares), PURA VIDA INVESTMENTS, LLC (18,056,274 shares), AWM Investment Company, Inc. (7,254,222 shares), VANGUARD GROUP INC (4,359,202 shares), Defender Capital, LLC. (2,272,930 shares), BlackRock Inc. (1,418,408 shares), GEODE CAPITAL MANAGEMENT, LLC (992,454 shares), MILLENNIUM MANAGEMENT LLC (561,361 shares), Schonfeld Strategic Advisors LLC (423,900 shares), and STATE STREET CORP (281,845 shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.